MWAFMR Career Development Workshop
Joumana T. Chaiban, MD, FACE
UIC/Advocate Christ Medical Center
After completing her Endocrinology Fellowship at Case Western Reserve University in Cleveland, Ohio, Dr Chaiban joined Saint Vincent Charity Medical Center where she was the Medical Director for the Joslin Diabetes Affiliate and then served as the Head of their Endocrinology Division and Chairperson of the IRB committee. She joined the Division of Endocrinology, Metabolism and Lipid Research at Washington University in July 2015. She practices General Endocrinology with a particular interest in Diabetes and Obesity.
Dawn Belt Davis, MD, PhD
University of Wisconsin – Madison
Dr. Davis runs a federally funded research lab focused on pancreatic beta cell biology. She focuses on understanding the mechanisms underlying the growth response in the beta cell and in beta cell death or apoptosis. Dr. Davis also conducts clinical research in collaboration with a number of other investigators. She has led a study to understand the mechanisms of hypoglycemia in gastric bypass surgery patients and to test a novel treatment for this disorder. She has ongoing collaborative studies looking at biomarkers for diabetes, novel dietary interventions for weight loss and diabetes prevention, and the treatment of diabetes in hospitalized patients.
Matthew Churpek, MD, PhD, MPH
University of Chicago
Dr. Churpek is an Assistant Professor of Medicine in the Section of Pulmonary and Critical Care at the University of Chicago. His research involves using electronic health record data to develop machine learning models to detect clinical deterioration in hospitalized patients. Dr. Churpek’s work has been supported by NIH K08 and R01 awards and an American Thoracic Society Foundation Recognition Award for Outstanding Early Career Investigators.
Lorraine B. Ware, MD
Vanderbilt University School of Medicine
Dr. Ware is a physician scientist and practicing intensivist at Vanderbilt University in the Division of Allergy, Pulmonary and Critical Care Medicine. Her research program focuses on Acute Respiratory Distress Syndrome including pathogenesis, biomarkers for diagnosis and prognosis and development of new targeted therapies. She is actively engaged in mentoring the next generation of physician scientists as director of an NIH T32 training grant, director of the Vanderbilt Medical Scholars medical student research program and as a faculty advisor to the Vanderbilt MSTP program.
Max Miller Lecture in Diabetes Research
Laurie J. Goodyear, PhD
Harvard Medical School
Dr. Laurie J. Goodyear received her B.S. from Springfield College in Massachusetts, her M.S. from the University of South Carolina, and her Ph.D. from the University of Vermont. She is Professor of Medicine at Harvard Medical School and a Senior Investigator at the Joslin Diabetes Center and. At Joslin, she serves as the Co-Head of the Section on Integrative Physiology and Metabolism, the Director of the NIH-funded Diabetes Research Center Animal Physiology Core, and the Director of the Clinical Exercise Physiology Research Laboratory. She has received numerous awards and honors, has published more than 200 papers and has given over 160 invited lectures at national and international conferences. The Goodyear laboratory investigates the underlying molecular mechanisms that mediate the beneficial effects of exercise to improve metabolic health. The Goodyear lab has made numerous, fundamental discoveries on how exercise regulates multiple signaling pathways in skeletal muscle, most notably her studies of AMPK. Currently, Dr. Goodyear is the PI of a Preclinical Animal Study Site (PASS) as part of the NIH-funded Molecular Transducers of Physical Activity in Humans Consortium (MoTrPAC), the goal of which is to determine the molecular footprint underlying the benefits of exercise on health. In addition to the consortium work, her lab has recently conducted groundbreaking studies in two areas of investigation. First, they have shown that exercise training causes adaptations to adipose tissue that improve overall glucose homeostasis. Second, they have discovered that maternal and paternal exercise has profound beneficial effects on the metabolic health of adult offspring, and elucidated novel epigenetic mechanisms for these effects. All of this work has important ramifications for the prevention and treatment of numerous chronic diseases in humans.
Terry D. Hinds, Jr., PhD
University of Toledo
Dr. Hinds obtained his BS in Biology from Shawnee State University and his PhD in Medical Sciences, Cardiovascular and Metabolic Diseases at the University of Toledo. He also completed a postdoctoral fellowship at University of Toledo and joined the faculty as an assistant professor in the Department of Physiology and Pharmacology in 2013. He also has joint appointments with the Department of Urology and with the Department of Kinesiology at University of North Carolina – Charlotte. His lab looks at how nuclear receptors signal for organismal metabolic balance and glucose homeostasis, including in cancer. Recently, his lab discovered an unexpected role for bilirubin as a ligand for nuclear receptors (PPARalpha) to attenuate metabolic diseases. This work has opened new avenues for therapy and drug targeting, and has led to two published international patents.
Brian T. O'Neill, MD, PhD
University of Iowa Carver College of Medicine
Brian O’Neill is an assistant professor and endocrinologist at the University of Iowa, Carver College of Medicine. He received his MD/PhD from the University of Utah and completed post-graduate training at Beth Israel Deaconess Medical Center and Joslin Diabetes Center, affiliates of Harvard Medical School. There Dr. O’Neill discovered that insulin receptors and IGF-1 receptors coordinate muscle growth and suppress atrophy by regulating FoxO transcription factors. Dr. O’Neill’s current and future plans involve investigating the roles of insulin signaling and FoxO regulation in the control of muscle strength and mitochondrial metabolism, in hopes of identifying the abnormalities that occur in the diabetic state. The ultimate goal of Dr. O’Neill’s research is to provide therapeutic targets that benefit muscle energy production in diabetes, speed recovery after severe illness or surgery, and prevent disability.
Bradley E. Britigan, MD
University of Nebraska Medical Center
A Minnesota native who grew up in St. Louis, Dr. Britigan, an internal medicine/infectious disease specialist, was named dean of the UNMC College of Medicine in 2011 after seven years at the University of Cincinnati as chair of internal medicine which was preceded by 17 years at the University of Iowa. He also has had a 25-year relationship with the VA. Dr. Britigan also serves as president of UNMC's partner, Nebraska Medicine.
Dr. Britigan places a high value on research. His own research focuses on bacterial infections of the lungs. During his academic career, his research has been primarily funded by the National Institutes of Health and the VA. He is also a member of the American Society of Clinical Investigation and the Association of American Physicians.
Department Chair Session I ~ University of Michigan
John M. Carethers, MD, Chair
Dr. Carethers' research interests include familial cancer and polyposis syndromes, mechanisms of tumor progression, tumor genetics, tumor markers, DNA mismatch repair, molecular pathology, TGF-beta superfamily signaling in cancer progression, and colorectal cancer disparities.
Dr. Carethers' clinical interests are f
amilial colon cancer syndromes, including familial adenomatous polyposis (FAP), Gardner, Peutz-Jeghers, Lynch, hereditary nonpolyposis colorectal cancer (HNPCC), juvenile polyposis, hyperplastic polyposis, and colorectal cancer.
Farsad Afshinnia, MD
Dr. Afshinnia joined the nephrology fellowship program as a fellow at the University of Michigan in 2010. After graduation he then joined the faculty at the division of nephrology at Michigan Medicine in 2012. Currently, he is in the 4th year of a K08 award. He has published over 30 original research papers. His research interests are application of metabolomics in biomarker discovery and risk stratification at early stage.
Yogendra Kanthi, MD
Dr. Kanthi is a Cardiologist and Vascular Medicine specialist at the University of Michigan. He completed his residency (2008) and served as Chief Medical Resident (2009) in Internal Medicine at University Hospitals Case Medical Center in Cleveland. He completed clinical fellowships in Cardiology (2013) and Vascular Medicine (2014) and a research fellowship in vascular biology at the University of Michigan. His areas of clinical interest include peripheral vascular disease, venous thromboembolism, chronic venous disease, general and preventive cardiology, aneurysmal disease, aortic disease and anticoagulation. He has an active translational research laboratory investigating the mechanisms of inflammation and thrombosis in vascular biology.
Hallie Prescott, MD, MSc
Dr. Prescott is an Assistant Professor in pulmonary/critical care and at University of Michigan and the Ann Arbor VA hospital. Her research examines the impact of sepsis on patient’ long-term health. She is vice chair of the Surviving Sepsis Campaign Guidelines and a council member of the International Sepsis Forum.
Department Chair Session II ~ Loyola University
Ravi Durvasula, MD, Chair
Dr. Durvasula earned his medical degree from McGill University in Montreal. He completed a residency in internal medicine at Baylor College of Medicine/Methodist Hospital in Houston, where he was chief medical resident. He completed a fellowship in infectious diseases at Yale University School of Medicine and was awarded the prestigious physician postdoctoral fellowship of the Howard Hughes Medical Institute. He is board certified in internal medicine and infectious diseases.
In 2017 Dr. Durvasula was named chair of the department of medicine of Loyola Medicine and Loyola University Chicago Stritch School of Medicine. He held senior leadership positions at Yale University and the Veterans Administration and has conducted groundbreaking research in global infectious diseases. Most recently, he was a professor of medicine and infectious diseases and director of the Center for Global Health at the University of New Mexico School of Medicine. The center has partnered with 13 medical centers in India, Kenya, China and Colombia.
Gregory Aubert, MD, PhD
MD-PhD from University of Lausanne Switzerland, Postdoctoral training at Sanford Burnham Medical research Institute in Dr. D. P. Kelly laboratory, Internal Medicine Residency at UT Southwestern, Cardiology Fellowship at Northwestern University in the Physician scientist training program.
Erin Lowery, MD, MS
Erin Lowery is an Associate Professor of Medicine and Pediatrics at Loyola University Chicago. She completed an adult pulmonary and critical care fellowship at Loyola University Medical Center and her clinic expertise is in cystic fibrosis and lung transplant. Dr. Lowery is supported by the National Institute of Alcohol Abuse and Alcoholism and the Cystic Fibrosis Foundation, and her research focuses on examining alcohol misuse in the context of lung transplantation and the advanced lung disease, the use of alcohol biomarkers to identify alcohol misuse, the impact alcohol misuse has on health outcomes, and alcohol's role in impairing airway inflammation.
Nasheed Hossain, MD
Assistant Professor of Medicine and junior lead for Cancer Cell Therapies at Loyola University. Has a research focus on the T-cell biology of Cellular Immune Therapy and how this may enhance clinical efficacy and reduce toxicities.
John B. Hickam Endowed Lecturer
Ariel Feldstein, MD
University of California, San Diego
Dr. Ariel Feldstein is Chief of the Gastroenterology, Hepatology & Nutrition Division at Rady Children's Hospital-San Diego and a Professor of Pediatrics at UC San Diego School of Medicine. After graduating from the Univ. of Buenos Aires and completing a postdoctoral program in physiology at the Mayo Clinic, Dr. Feldstein went on to become the Director of Research for the Pediatric Institute at the Cleveland Clinic before moving to San Diego in 2011. He is a renowned Pediatric Hepatologist who pioneered the development of non-invasive blood tests to monitor liver damage and discovered novel targets for NASH and liver fibrosis treatment for which he holds various patents. He is an innovator and an entrepreneur being the founder of two Biotech Companies, Torrey Pines Metabolic Health Labs and Jecure Therapeutics (acquired by Genentech/Roche in 2018). His lab focuses on molecular mechanisms of acute and chronic liver injury, their links to fibrosis and hepatocarcinogenesis, and serum-based biomarkers to monitor liver damage non-invasively.
Robert McCullumsmith, MD, PhD
University of Toledo Medical Center
Dr. McCullumsmith studied biochemistry (BS) at Indiana University, then pursued joint MD, PhD degrees at the University of Michigan. Following a research-track residency in Psychiatry at the University of Michigan, he joined the faculty and began to study abnormalities of glutamate transporter expression in severe mental illness. Dr. McCullumsmith was promoted to Associate Professor with Tenure while at the Department of Psychiatry and Neurobiology at the University of Alabama-Birmingham. Dr. McCullumsmith relocated to the University of Cincinnati in 2013, and sees patients at the Cincinnati Veteran’s Affairs Medical Center and the University of Cincinnati Department of Psychiatry.